Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 9/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24908501 | 0.84 | NOTUM (0.55) | NOTUMHSP90AA1PIN1KDM1AIDO1 | |
| SCHEMBL25043786 | 0.80 | RXRA (0.38) | NOTUM | |
| SCHEMBL24908598 | 0.79 | NOTUM (0.54) | NOTUMHSP90AA1PIN1KDM1ACYP19A1 | |
| SCHEMBL2582033 | 0.78 | CA1 (0.39) | NOTUMKDM4EPTGS2 | |
| SCHEMBL12156459 | 0.78 | P2RX7 (0.50) | NOTUM | |
| SCHEMBL13469380 | 0.75 | NOTUM (0.59) | NOTUMHSP90AA1PIN1KDM1A | |
| SCHEMBL20097511 | 0.73 | NOTUM (0.58) | NOTUMPTGS2CYP19A1 | |
| SCHEMBL2587519 | 0.72 | HTT (0.44) | PTGS2IDO1TDO2 | |
| SCHEMBL23451495 | 0.71 | NOTUM (1.00) | NOTUMKDM4E | |
| SCHEMBL17780718 | 0.71 | NOTUM (0.72) | NOTUMKDM4EHSP90AA1PIN1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ - FIOCRUZ (BR) | 2011-11-03 | — | — | US | claimed |
| US-20090054501-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | BOECHAT NUBIA | 2009-02-26 | — | — | US | claimed |
| EP-1976832-A2 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | Fundacao Oswaldo Cruz - Fiocruz (BR) | 2008-10-08 | — | — | EP | claimed |
| WO-2007019660-A2 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | Fundação Oswaldo Cruz - FIOCRUZ (BR) | 2007-02-22 | — | — | WO | claimed |
| US-8796316-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2014-08-05 | — | — | US | disclosed |
| US-8796316-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2014-08-05 | — | — | US | disclosed |
| US-8796316-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2014-08-05 | — | — | US | disclosed |
| US-20130274298-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ (BR) | 2013-10-17 | — | — | US | disclosed |
| US-20130274298-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ (BR) | 2013-10-17 | — | — | US | disclosed |
| US-20130274298-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ (BR) | 2013-10-17 | — | — | US | disclosed |
| US-8436027-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2013-05-07 | — | — | US | disclosed |
| US-8436027-B2 | Azole compounds used as tuberculostatic and leishmanicide agents | Fundacão Oswaldo Cruz—FIOCRUZ (BR) | 2013-05-07 | — | — | US | disclosed |
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ - FIOCRUZ (BR) | 2011-11-03 | — | — | US | disclosed |
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ - FIOCRUZ (BR) | 2011-11-03 | — | — | US | disclosed |
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | FUNDACAO OSWALDO CRUZ - FIOCRUZ (BR) | 2011-11-03 | — | — | US | disclosed |
| US-20090054501-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | BOECHAT NUBIA | 2009-02-26 | — | — | US | disclosed |
| US-20090054501-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | BOECHAT NUBIA | 2009-02-26 | — | — | US | disclosed |
| US-20090054501-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | BOECHAT NUBIA | 2009-02-26 | — | — | US | disclosed |
| EP-1976832-A2 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | Fundacao Oswaldo Cruz - Fiocruz (BR) | 2008-10-08 | — | — | EP | disclosed |
| WO-2007019660-A2 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | Fundação Oswaldo Cruz - FIOCRUZ (BR) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274298-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CYP51A1, IPO5, TBC1D5 | NOTUM 1619/4885KDM4E 2209/4885TP53 2038/4885 |
| US-20090054501-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CBR3, NOX3, NR2C2 | NOTUM 1774/4885KDM4E 3105/4885TP53 3889/4885 |
| US-20110269803-A1 | AZOLE COMPOUNDS USED AS TUBERCULOSTATIC AND LEISHMANICIDE AGENTS | CBR3, NOX3, NR2C2 | NOTUM 1936/4885KDM4E 3060/4885TP53 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.